The addition of pembrolizumab to chemotherapy provided long-term benefit to a subset of patients with advanced non-small cell lung cancer, according to study results presented during the ASCO20 Virtual Scientific Program.

Relugolix demonstrated superiority over leuprolide acetate in sustained testosterone suppression through 48 weeks among men with advanced prostate cancer, according to study results presented during the ASCO20 Virtual Scientific Program.

A recent poll showed that 75% of patients want to return to their doctor’s office after remaining home during the COVID-19 pandemic.

The average patient who received hydroxychloroquine for a rheumatic disease was unlikely to achieve the total serum or plasma concentration necessary to inhibit the coronavirus in vitro, particularly at dosages of less than 400 mg per day, according to data published in The Journal of Rheumatology.

In the second part of a three-part video discussion, Leela K. Raju, MD, and Sonya Dhar, MD, discuss safety issues for ophthalmologists reopening clinics and what they anticipate as they return to the clinic.

Rheumatologists may consider “cautious tapering” of DMARDs in patients with psoriatic arthritis who achieve sustained remission, according to a 2019 update to EULAR recommendations published in Annals of the Rheumatic Diseases.

Patients with moderate COVID-19 who received remdesivir for 5 days were 65% more likely to show clinical improvement compared with those who received usual care, according to results from a phase 3 clinical trial released by the manufacturer.

U.S. President Donald J. Trump announced last week that the U.S. would withdraw from WHO, citing criticism of its response to the COVID-19 pandemic and its relationship with China.

Researchers from the University of Kentucky are conducting a clinical trial to evaluate the effectiveness of azithromycin, ivermectin and camostat mesylate alone or combined with hydroxychloroquine in high-risk patients with COVID-19.

A psilocybin formulation was well tolerated among healthy patients, which supports research into its use for treatment-resistant depression, according to data presented at the American Society of Clinical Psychopharmacology Annual Meeting.